Passage Bio Key Executives
This section highlights Passage Bio's key executives, including their titles and compensation details.
Find Contacts at Passage Bio
(Showing 0 of )
Passage Bio Earnings
This section highlights Passage Bio's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
$0.32
Stock Price
$20.01M
Market Cap
60
Employees
Philadelphia, PA
Location
Financial Statements
Access annual & quarterly financial statements for Passage Bio, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $3.72M | $3.68M | $1.54M | $800.00K |
| Gross Profit | $- | $-3.72M | $-3.68M | $-1.54M | $-800.00K |
| Gross Profit Ratio | 0.00% | - | - | - | - |
| Research and Development Expenses | $40.18M | $61.42M | $86.05M | $117.67M | $81.79M |
| General and Administrative Expenses | $24.99M | $41.58M | $49.34M | $60.06M | $30.11M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $24.99M | $41.58M | $49.34M | $60.06M | $30.11M |
| Other Expenses | $- | $5.39M | $- | $- | $- |
| Operating Expenses | $65.17M | $108.39M | $135.39M | $177.73M | $111.90M |
| Cost and Expenses | $- | $108.39M | $135.39M | $177.73M | $111.90M |
| Interest Income | $- | $5.60M | $2.27M | $343.00K | $670.00K |
| Interest Expense | $- | $- | $2.27M | $- | $- |
| Depreciation and Amortization | $- | $3.72M | $3.68M | $1.54M | $800.00K |
| EBITDA | $-70.40M | $-98.34M | $-138.39M | $-185.73M | $-112.90M |
| EBITDA Ratio | - | - | - | - | - |
| Operating Income | $-70.40M | $-108.39M | $-138.39M | $-185.73M | $-112.90M |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $5.63M | $6.33M | $2.27M | $343.00K | $670.00K |
| Income Before Tax | $-64.77M | $-102.06M | $-136.12M | $-185.39M | $-112.23M |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $- | $- | $731.00K | $6.11M | $-470.00K |
| Net Income | $-64.77M | $-102.06M | $-136.86M | $-191.50M | $-111.76M |
| Net Income Ratio | - | - | - | - | - |
| EPS | $-1.07 | $-1.86 | $-2.51 | $-3.59 | $-2.89 |
| EPS Diluted | $-1.07 | $-1.86 | $-2.51 | $-3.59 | $-2.89 |
| Weighted Average Shares Outstanding | 60.41M | 54.74M | 54.43M | 53.34M | 38.62M |
| Weighted Average Shares Outstanding Diluted | 60.41M | 54.74M | 54.43M | 53.34M | 38.62M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $5.91M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $800.00K | $806.00K | $807.00K | $1.00M | $978.00K | $978.00K | $946.00K | $929.00K | $921.00K | $883.00K | $669.00K | $460.00K | $203.00K | $211.00K | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-800.00K | $-806.00K | $5.11M | $-1.00M | $-978.00K | $-978.00K | $-946.00K | $-929.00K | $-921.00K | $-883.00K | $-669.00K | $-460.00K | $-203.00K | $-211.00K | $- | $- | $- | $- |
| Gross Profit Ratio | - | 0.00% | - | - | 86.35% | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $9.56M | $8.66M | $10.43M | $11.54M | $12.16M | $15.10M | $17.32M | $16.84M | $17.66M | $15.36M | $26.82M | $26.21M | $32.97M | $26.62M | $33.11M | $24.97M | $27.93M | $20.84M | $19.90M | $13.12M |
| General and Administrative Expenses | $4.71M | $7.25M | $6.51M | $6.51M | $6.29M | $8.18M | $8.06M | $19.05M | $10.59M | $10.66M | $12.99M | $15.10M | $17.19M | $14.98M | $15.42M | $12.46M | $10.12M | $7.79M | $7.40M | $4.79M |
| Selling and Marketing Expenses | $- | $- | $- | $-806.00K | $-807.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.71M | $7.25M | $6.51M | $5.71M | $5.48M | $8.18M | $8.06M | $19.05M | $10.59M | $10.66M | $12.99M | $15.10M | $17.19M | $14.98M | $15.42M | $12.46M | $10.12M | $7.79M | $7.40M | $4.79M |
| Other Expenses | $- | $4.79M | $438.00K | $1.34M | $1.69M | $1.56M | $1.53M | $1.54M | $- | $825.00K | $270.00K | $1.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $14.27M | $20.70M | $17.38M | $17.24M | $17.64M | $23.28M | $25.39M | $35.88M | $28.24M | $26.03M | $39.81M | $41.31M | $50.16M | $41.60M | $48.53M | $37.43M | $38.06M | $28.63M | $27.30M | $17.91M |
| Cost and Expenses | $14.27M | $20.70M | $17.38M | $18.05M | $18.45M | $23.28M | $25.39M | $35.88M | $28.24M | $26.03M | $39.81M | $41.31M | $50.16M | $41.60M | $48.53M | $37.43M | $38.06M | $28.63M | $27.30M | $17.91M |
| Interest Income | $- | $- | $- | $- | $1.50M | $- | $1.50K | $- | $1.17M | $825.00K | $270.00K | $1.00K | $6.00K | $186.00K | $99.00K | $52.00K | $112.00K | $99.00K | $132.00K | $327.00K |
| Interest Expense | $- | $- | $- | $- | $1.54M | $- | $- | $- | $1.17M | $825.00K | $270.00K | $1.00K | $6.00K | $186.00K | $99.00K | $52.00K | $112.00K | $99.00K | $132.00K | $327.00K |
| Depreciation and Amortization | $719.00K | $759.00K | $797.00K | $806.00K | $807.00K | $1.00M | $978.00K | $978.00K | $946.00K | $929.00K | $921.00K | $883.00K | $669.00K | $460.00K | $203.00K | $211.00K | $278.00K | $275.00K | $198.00K | $49.00K |
| EBITDA | $-13.55M | $-15.15M | $-16.14M | $-17.24M | $-17.64M | $-22.32M | $-24.41M | $-35.88M | $-26.12M | $-25.10M | $-38.89M | $-40.43M | $-49.49M | $-41.14M | $-48.33M | $-37.22M | $-37.78M | $-28.36M | $-27.11M | $-17.86M |
| EBITDA Ratio | - | - | - | - | -298.36% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-14.27M | $-20.70M | $-17.38M | $-18.05M | $-18.45M | $-28.67M | $-25.39M | $-35.88M | $-28.24M | $-27.53M | $-39.81M | $-42.81M | $-51.16M | $-47.10M | $-48.53M | $-38.93M | $-39.06M | $-28.63M | $-27.30M | $-17.91M |
| Operating Income Ratio | - | - | - | - | -312.01% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $1.54M | $1.36M | $1.39M | $1.34M | $1.69M | $1.56M | $1.53M | $1.54M | $1.17M | $825.00K | $270.00K | $1.00K | $6.00K | $186.00K | $99.00K | $52.00K | $112.00K | $99.00K | $132.00K | $327.00K |
| Income Before Tax | $-12.72M | $-19.34M | $-15.99M | $-16.71M | $-16.76M | $-27.11M | $-23.86M | $-34.34M | $-27.07M | $-26.70M | $-39.54M | $-42.81M | $-51.15M | $-46.91M | $-48.44M | $-38.88M | $-38.94M | $-28.53M | $-27.17M | $-17.59M |
| Income Before Tax Ratio | - | - | - | - | -283.46% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $- | $- | $- | $-1 | $3.48M | $-958.00K | $-978.00K | $-1.54M | $-1.17M | $-825.00K | $-270.00K | $-1.00K | $-6.00K | $-186.00K | $-99.00K | $2.90M | $-112.00K | $-99.00K | $-132.00K | $-654.00K |
| Net Income | $-12.72M | $-19.34M | $-15.99M | $-16.71M | $-16.76M | $-27.11M | $-23.86M | $-32.79M | $-25.90M | $-25.88M | $-39.27M | $-42.81M | $-51.15M | $-46.91M | $-48.44M | $-38.88M | $-38.94M | $-28.53M | $-27.17M | $-17.59M |
| Net Income Ratio | - | - | - | - | -283.46% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-0.21 | $-0.31 | $-0.26 | $-0.30 | $-0.31 | $-0.49 | $-0.44 | $-0.60 | $-0.47 | $-0.48 | $-0.72 | $-0.79 | $-0.95 | $-0.87 | $-0.90 | $-0.76 | $-0.85 | $-0.63 | $-0.60 | $-1.00 |
| EPS Diluted | $-0.21 | $-0.31 | $-0.26 | $-0.30 | $-0.31 | $-0.49 | $-0.44 | $-0.60 | $-0.47 | $-0.48 | $-0.72 | $-0.79 | $-0.95 | $-0.87 | $-0.90 | $-0.76 | $-0.85 | $-0.63 | $-0.60 | $-1.00 |
| Weighted Average Shares Outstanding | 60.41M | 61.76M | 61.68M | 56.30M | 54.94M | 54.79M | 54.68M | 54.62M | 54.61M | 54.47M | 54.39M | 54.28M | 54.00M | 54.00M | 53.89M | 51.33M | 45.61M | 45.50M | 45.39M | 17.62M |
| Weighted Average Shares Outstanding Diluted | 60.41M | 61.76M | 61.68M | 56.30M | 54.94M | 54.79M | 54.68M | 54.62M | 54.61M | 54.47M | 54.39M | 54.28M | 54.00M | 54.00M | 53.89M | 51.33M | 45.61M | 45.50M | 45.39M | 17.62M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $37.57M | $21.71M | $34.60M | $128.97M | $135.00M |
| Short Term Investments | $39.18M | $92.58M | $155.01M | $186.81M | $169.81M |
| Cash and Short Term Investments | $76.76M | $114.29M | $189.61M | $315.77M | $304.82M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $2.06M | $3.67M | $7.43M | $9.29M | $12.37M |
| Total Current Assets | $78.81M | $117.96M | $197.04M | $325.07M | $317.18M |
| Property Plant Equipment Net | $23.13M | $32.15M | $42.24M | $23.81M | $2.79M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $463.00K | $433.00K | $4.27M | $6.20M | $5.23M |
| Total Non-Current Assets | $23.60M | $32.59M | $46.51M | $30.01M | $8.03M |
| Other Assets | $- | $- | $- | $-0 | $2.79M |
| Total Assets | $102.41M | $150.54M | $243.55M | $355.08M | $328.01M |
| Account Payables | $742.00K | $1.30M | $4.07M | $9.45M | $5.26M |
| Short Term Debt | $3.69M | $3.37M | $6.55M | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $14.93M | $11.67M | $7.74M | $20.05M | $15.91M |
| Total Current Liabilities | $19.36M | $16.34M | $18.35M | $29.50M | $21.18M |
| Long Term Debt | $21.79M | $22.92M | $23.83M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $6.92M | $2.12M |
| Total Non-Current Liabilities | $21.79M | $22.92M | $23.83M | $6.92M | $2.12M |
| Other Liabilities | $- | $- | $- | $0 | $- |
| Total Liabilities | $41.15M | $39.26M | $42.18M | $36.42M | $23.29M |
| Preferred Stock | $- | $- | $- | $- | $328.01M |
| Common Stock | $6.00K | $5.00K | $5.00K | $5.00K | $4.00K |
| Retained Earnings | $-659.24M | $-594.47M | $-492.41M | $-356.28M | $-170.90M |
| Accumulated Other Comprehensive Income Loss | $8.00K | $-43.00K | $-966.00K | $-413.00K | $-12.00K |
| Other Total Stockholders Equity | $720.48M | $705.79M | $694.73M | $675.35M | $475.62M |
| Total Stockholders Equity | $61.26M | $111.28M | $201.37M | $318.66M | $304.71M |
| Total Equity | $61.26M | $111.28M | $201.37M | $318.66M | $304.71M |
| Total Liabilities and Stockholders Equity | $102.41M | $150.54M | $243.55M | $355.08M | $328.01M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $102.41M | $150.54M | $243.55M | $355.08M | $328.01M |
| Total Investments | $39.18M | $92.58M | $155.01M | $186.81M | $169.81M |
| Total Debt | $25.48M | $26.29M | $27.11M | $- | $- |
| Net Debt | $-12.10M | $4.58M | $-7.49M | $-128.97M | $-135.00M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $37.57M | $32.29M | $24.77M | $36.77M | $21.71M | $33.58M | $30.29M | $33.37M | $34.60M | $62.57M | $91.13M | $101.61M | $128.97M | $162.89M | $215.46M | $249.52M | $135.00M | $200.57M | $353.42M | $366.83M |
| Short Term Investments | $39.18M | $52.53M | $67.00M | $67.75M | $92.58M | $99.20M | $121.19M | $134.40M | $155.01M | $151.19M | $148.12M | $165.48M | $186.81M | $191.51M | $192.34M | $188.07M | $169.81M | $135.13M | $- | $- |
| Cash and Short Term Investments | $76.76M | $84.83M | $91.77M | $104.53M | $114.29M | $132.78M | $151.48M | $167.77M | $189.61M | $213.76M | $239.25M | $267.09M | $315.77M | $354.40M | $407.80M | $437.59M | $304.82M | $335.70M | $353.42M | $366.83M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $2.06M | $2.36M | $3.23M | $3.77M | $3.67M | $2.93M | $2.15M | $3.85M | $7.43M | $8.77M | $11.33M | $15.91M | $9.29M | $12.07M | $11.04M | $13.36M | $12.37M | $13.81M | $14.81M | $15.26M |
| Total Current Assets | $78.81M | $87.22M | $95.00M | $108.29M | $117.96M | $135.71M | $153.62M | $171.62M | $197.04M | $222.52M | $250.58M | $283.00M | $325.07M | $366.47M | $418.84M | $450.95M | $317.18M | $349.51M | $368.23M | $382.09M |
| Property Plant Equipment Net | $23.13M | $24.07M | $29.88M | $31.58M | $32.15M | $33.11M | $39.64M | $41.19M | $42.24M | $42.81M | $43.62M | $44.50M | $23.81M | $17.77M | $13.48M | $6.57M | $2.79M | $915.00K | $1.10M | $1.14M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $463.00K | $463.00K | $516.00K | $662.00K | $433.00K | $433.00K | $433.00K | $433.00K | $4.27M | $4.72M | $5.22M | $5.72M | $6.20M | $6.71M | $7.21M | $7.65M | $5.23M | $8.27M | $8.77M | $9.20M |
| Total Non-Current Assets | $23.60M | $24.54M | $30.39M | $32.24M | $32.59M | $33.55M | $40.07M | $41.62M | $46.51M | $47.53M | $48.84M | $50.22M | $30.01M | $24.47M | $20.69M | $14.22M | $8.03M | $9.18M | $9.87M | $10.34M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.79M | $- | $- | $- |
| Total Assets | $102.41M | $111.75M | $125.39M | $140.53M | $150.54M | $169.26M | $193.70M | $213.24M | $243.55M | $270.05M | $299.42M | $333.22M | $355.08M | $390.94M | $439.52M | $465.17M | $328.01M | $358.69M | $378.10M | $392.43M |
| Account Payables | $742.00K | $1.49M | $621.00K | $1.69M | $1.30M | $2.75M | $3.38M | $3.03M | $4.07M | $4.51M | $8.21M | $9.13M | $9.45M | $8.98M | $16.40M | $6.25M | $5.26M | $3.44M | $7.21M | $2.53M |
| Short Term Debt | $3.69M | $3.73M | $7.40M | $3.67M | $6.75M | $6.70M | $6.65M | $6.61M | $3.27M | $6.50M | $6.46M | $6.24M | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $14.93M | $11.73M | $4.36M | $7.48M | $8.30M | $10.36M | $9.84M | $7.60M | $11.01M | $10.61M | $12.46M | $12.11M | $20.05M | $13.27M | $14.85M | $13.22M | $15.91M | $15.66M | $6.92M | $2.70M |
| Total Current Liabilities | $19.36M | $16.95M | $12.38M | $12.84M | $16.34M | $19.81M | $19.87M | $17.24M | $18.35M | $21.62M | $27.13M | $27.48M | $29.50M | $22.25M | $31.25M | $19.47M | $21.18M | $19.10M | $14.13M | $5.23M |
| Long Term Debt | $21.79M | $22.09M | $22.45M | $22.81M | $22.92M | $23.17M | $23.41M | $23.65M | $23.83M | $24.04M | $24.24M | $24.43M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $2.00M | $- | $- | $- | $- | $6.92M | $6.46M | $6.01M | $4.20M | $2.12M | $685.00K | $567.00K | $533.00K |
| Total Non-Current Liabilities | $21.79M | $22.09M | $22.45M | $22.81M | $22.92M | $23.17M | $23.41M | $25.65M | $23.83M | $24.04M | $24.24M | $24.43M | $6.92M | $6.46M | $6.01M | $4.20M | $2.12M | $685.00K | $567.00K | $533.00K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $41.15M | $39.04M | $34.84M | $35.65M | $39.26M | $42.98M | $43.28M | $42.89M | $42.18M | $45.66M | $51.37M | $51.91M | $36.42M | $28.71M | $37.26M | $23.67M | $23.29M | $19.79M | $14.70M | $5.76M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $358.69M | $378.10M | $392.43M |
| Common Stock | $6.00K | $6.00K | $6.00K | $6.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K |
| Retained Earnings | $-659.24M | $-646.51M | $-627.17M | $-611.18M | $-594.47M | $-577.71M | $-550.60M | $-526.74M | $-492.41M | $-465.33M | $-438.63M | $-399.09M | $-356.28M | $-305.13M | $-258.21M | $-209.78M | $-170.90M | $-131.95M | $-103.42M | $-76.25M |
| Accumulated Other Comprehensive Income Loss | $8.00K | $32.00K | $-67.00K | $-69.00K | $-43.00K | $-192.00K | $-340.00K | $-427.00K | $-966.00K | $-1.47M | $-1.58M | $-1.33M | $-413.00K | $33.00K | $19.00K | $-7.00K | $-12.00K | $-40.00K | $-378.10M | $-392.43M |
| Other Total Stockholders Equity | $720.48M | $719.19M | $717.79M | $716.12M | $705.79M | $704.17M | $701.35M | $697.52M | $694.73M | $691.19M | $688.25M | $681.73M | $675.35M | $667.32M | $660.46M | $651.28M | $475.62M | $470.89M | $844.91M | $855.34M |
| Total Stockholders Equity | $61.26M | $72.72M | $90.56M | $104.88M | $111.28M | $126.28M | $150.41M | $170.35M | $201.37M | $224.40M | $248.05M | $281.31M | $318.66M | $362.23M | $402.27M | $441.50M | $304.71M | $338.90M | $363.40M | $386.67M |
| Total Equity | $61.26M | $72.72M | $90.56M | $104.88M | $111.28M | $126.28M | $150.41M | $170.35M | $201.37M | $224.40M | $248.05M | $281.31M | $318.66M | $362.23M | $402.27M | $441.50M | $304.71M | $338.90M | $363.40M | $386.67M |
| Total Liabilities and Stockholders Equity | $102.41M | $111.75M | $125.39M | $140.53M | $150.54M | $169.26M | $193.70M | $213.24M | $243.55M | $270.05M | $299.42M | $333.22M | $355.08M | $390.94M | $439.52M | $465.17M | $328.01M | $358.69M | $378.10M | $392.43M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $102.41M | $111.75M | $125.39M | $140.53M | $150.54M | $169.26M | $193.70M | $213.24M | $243.55M | $270.05M | $299.42M | $333.22M | $355.08M | $390.94M | $439.52M | $465.17M | $328.01M | $358.69M | $378.10M | $392.43M |
| Total Investments | $39.18M | $52.53M | $67.00M | $67.75M | $92.58M | $99.20M | $121.19M | $134.40M | $155.01M | $151.19M | $148.12M | $165.48M | $186.81M | $191.51M | $192.34M | $188.07M | $169.81M | $135.13M | $- | $- |
| Total Debt | $25.48M | $25.82M | $26.15M | $26.48M | $26.29M | $26.52M | $26.74M | $26.95M | $27.11M | $27.29M | $27.47M | $27.55M | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-12.10M | $-6.47M | $1.38M | $-10.29M | $4.58M | $-7.06M | $-3.55M | $-6.42M | $-7.49M | $-35.28M | $-63.66M | $-74.06M | $-128.97M | $-162.89M | $-215.46M | $-249.52M | $-135.00M | $-200.57M | $-353.42M | $-366.83M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-64.77M | $-102.06M | $-136.12M | $-185.39M | $-112.23M |
| Depreciation and Amortization | $3.08M | $3.72M | $3.68M | $1.54M | $800.00K |
| Deferred Income Tax | $- | $- | $- | $2.78M | $633.00K |
| Stock Based Compensation | $5.82M | $10.92M | $18.95M | $32.69M | $14.58M |
| Change in Working Capital | $4.20M | $5.34M | $-8.49M | $11.42M | $14.44M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-556.00K | $-2.79M | $-5.41M | $2.20M | $4.59M |
| Other Working Capital | $4.76M | $8.13M | $-3.08M | $9.22M | $9.85M |
| Other Non Cash Items | $3.71M | $3.82M | $3.77M | $10.07M | $1.26M |
| Net Cash Provided by Operating Activities | $-47.96M | $-78.26M | $-118.21M | $-126.88M | $-80.52M |
| Investments in Property Plant and Equipment | $-34.00K | $-146.00K | $-5.27M | $-25.64M | $-1.65M |
| Acquisitions Net | $- | $- | $3.00M | $8.00M | $500.00K |
| Purchases of Investments | $-88.17M | $-129.43M | $-157.84M | $-202.55M | $-266.06M |
| Sales Maturities of Investments | $143.15M | $194.81M | $188.31M | $182.37M | $95.60M |
| Other Investing Activities | $- | $- | $-3.00M | $-8.00M | $-500.00K |
| Net Cash Used for Investing Activities | $54.95M | $65.24M | $25.20M | $-45.81M | $-172.11M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $8.74M | $135.00K | $304.00K | $166.69M | $228.47M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $132.00K | $- | $-1.35M | $-37.00K | $284.00K |
| Net Cash Used Provided by Financing Activities | $8.87M | $135.00K | $-1.35K | $166.66K | $228.75M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $15.86M | $-12.89M | $-94.36M | $-6.04M | $-23.87M |
| Cash at End of Period | $37.57M | $21.71M | $34.60M | $128.97M | $135.00M |
| Cash at Beginning of Period | $21.71M | $34.60M | $128.97M | $135.00M | $158.87M |
| Operating Cash Flow | $-47.96M | $-78.26M | $-118.21M | $-126.88M | $-80.52M |
| Capital Expenditure | $-34.00K | $-146.00K | $-5.27M | $-25.64M | $-1.65M |
| Free Cash Flow | $-47.99M | $-78.41M | $-123.48M | $-152.52M | $-82.17M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-12.72M | $-19.34M | $-15.99M | $-16.71M | $-16.76M | $-27.11M | $-23.86M | $-34.34M | $-27.07M | $-26.70M | $-39.54M | $-42.81M | $-51.15M | $-46.91M | $-48.44M | $-38.88M | $-38.94M | $-28.53M | $-27.17M | $-17.59M |
| Depreciation and Amortization | $719.00K | $-403.00K | $797.00K | $806.00K | $807.00K | $958.00K | $978.00K | $978.00K | $946.00K | $929.00K | $921.00K | $883.00K | $669.00K | $460.00K | $203.00K | $211.00K | $278.00K | $275.00K | $198.00K | $49.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-4.66M | $11.28M | $8.06M | $- | $- | $- | $- | $- | $- | $889.00K | $498.00K | $848.00K | $586.00K | $47.00K | $- | $- |
| Stock Based Compensation | $1.25M | $1.40M | $1.58M | $1.59M | $1.57M | $2.82M | $3.74M | $2.78M | $3.48M | $2.86M | $6.28M | $6.34M | $7.58M | $6.82M | $8.56M | $9.74M | $4.32M | $4.03M | $3.85M | $2.37M |
| Change in Working Capital | $2.68M | $3.84M | $339.00K | $-4.17M | $-4.29M | $-906.00K | $2.30M | $8.23M | $-940.00K | $-2.04M | $5.98M | $-11.49M | $10.13M | $-8.26M | $13.04M | $-3.49M | $3.21M | $6.53M | $11.37M | $-6.67M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-747.00K | $868.00K | $-1.07M | $389.00K | $-1.47M | $-634.00K | $357.00K | $-1.04M | $-433.00K | $-3.74M | $-280.00K | $-957.00K | $116.00K | $-7.79M | $9.28M | $592.00K | $1.78M | $-3.72M | $6.19M | $331.00K |
| Other Working Capital | $3.43M | $2.97M | $1.41M | $-4.56M | $-2.81M | $-272.00K | $1.95M | $9.27M | $-507.00K | $1.70M | $6.26M | $-10.54M | $10.02M | $-473.00K | $3.75M | $-4.08M | $1.43M | $10.24M | $5.18M | $-7.00M |
| Other Non Cash Items | $-365.00K | $7.06M | $141.00K | $2.37M | $3.81M | $-6.21M | $-8.37M | $-98.00K | $-433.00K | $1.55M | $276.00K | $2.38M | $2.00M | $5.96M | $1.81M | $853.00K | $1.12M | $119.00K | $35.00K | $-15.00K |
| Net Cash Provided by Operating Activities | $-8.44M | $-7.45M | $-13.14M | $-18.93M | $-19.52M | $-19.16M | $-17.14M | $-22.45M | $-24.02M | $-23.39M | $-26.08M | $-44.71M | $-30.77M | $-41.06M | $-24.33M | $-30.72M | $-29.42M | $-17.53M | $-11.71M | $-21.85M |
| Investments in Property Plant and Equipment | $-14.00K | $-20.00K | $- | $- | $-13.00K | $-4.00K | $-103.00K | $-26.00K | $-474.00K | $-1.74M | $-831.00K | $-2.23M | $-7.32M | $-11.51M | $-5.51M | $-1.30M | $-1.30M | $-149.00K | $-94.00K | $-99.00K |
| Acquisitions Net | $- | $- | $- | $- | $-7.61K | $-22.45K | $-14.07K | $-21.24K | $3.00M | $4.51K | $-16.84K | $1.50M | $8.00M | $5.50M | $1.50M | $500.00K | $-96.10M | $- | $- | $- |
| Purchases of Investments | $-15.58M | $-21.77M | $-37.02M | $-13.81M | $-27.79M | $-28.11M | $-22.13M | $-51.40M | $-41.53M | $-57.43M | $-21.47M | $-37.40M | $-32.69M | $-37.71M | $-71.82M | $-60.33M | $-130.84M | $-135.22M | $- | $- |
| Sales Maturities of Investments | $29.27M | $36.76M | $38.06M | $39.06M | $35.41M | $50.57M | $36.20M | $72.64M | $38.65M | $54.41M | $38.31M | $56.94M | $36.40M | $37.67M | $67.08M | $41.23M | $95.60M | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $25.25K | $7.61K | $22.45K | $14.07K | $21.24K | $-3.00M | $-4.51K | $16.84K | $-1.50M | $-8.00M | $-5.50M | $-1.50M | $-500.00K | $96.10M | $-135.22M | $- | $- |
| Net Cash Used for Investing Activities | $13.68M | $14.97M | $1.05M | $25.25M | $7.60M | $22.45M | $13.97M | $21.22M | $-3.36M | $-4.76M | $16.00M | $17.31M | $-3.60M | $-11.55M | $-10.26M | $-20.40M | $-36.55M | $-135.37M | $-94.00K | $-99.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-50.00K | $50.00K | $8.74M | $46.00K | $- | $89.00K | $- | $61.00K | $79.00K | $243.00K | $49.00K | $383.00K | $44.00K | $505.00K | $165.81M | $284.00K | $- | $-1.64M | $229.90M |
| Common Stock Repurchased | $- | $50.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.60K | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $47.00K | $- | $35.00K | $- | $- | $- | $- | $- | $-649.00K | $-408.00K | $-406.00K | $49.00K | $72.00K | $44.00K | $18.00K | $-171.00K | $118.00K | $44.00K | $46.00K | $- |
| Net Cash Used Provided by Financing Activities | $47.00K | $- | $85.00K | $8.74M | $46.00K | $- | $89.00K | $- | $-588 | $-408 | $-406 | $49 | $455 | $44 | $523 | $165.63K | $402.00K | $44.00K | $-1.60M | $229.90M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-11.45M | $- | $11.45M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $5.28M | $7.52M | $-12.00M | $15.06M | $-11.87M | $3.29M | $-3.08M | $-1.23M | $-27.97M | $-28.56M | $-10.48M | $-27.35M | $-33.92M | $-52.57M | $-34.06M | $114.52M | $-65.57M | $-152.85M | $-13.40M | $207.95M |
| Cash at End of Period | $37.57M | $32.29M | $24.77M | $36.77M | $21.71M | $33.58M | $30.29M | $33.37M | $34.60M | $62.57M | $91.13M | $101.61M | $128.97M | $162.89M | $215.46M | $249.52M | $135.00M | $200.57M | $353.42M | $366.83M |
| Cash at Beginning of Period | $32.29M | $24.77M | $36.77M | $21.71M | $33.58M | $30.29M | $33.37M | $34.60M | $62.57M | $91.13M | $101.61M | $128.97M | $162.89M | $215.46M | $249.52M | $135.00M | $200.57M | $353.42M | $366.83M | $158.87M |
| Operating Cash Flow | $-8.44M | $-7.45M | $-13.14M | $-18.93M | $-19.52M | $-19.16M | $-17.14M | $-22.45M | $-24.02M | $-23.39M | $-26.08M | $-44.71M | $-30.77M | $-41.06M | $-24.33M | $-30.72M | $-29.42M | $-17.53M | $-11.71M | $-21.85M |
| Capital Expenditure | $-14.00K | $-20.00K | $- | $- | $-13.00K | $-4.00K | $-103.00K | $-26.00K | $-474.00K | $-1.74M | $-831.00K | $-2.23M | $-7.32M | $-11.51M | $-5.51M | $-1.30M | $-1.30M | $-149.00K | $-94.00K | $-99.00K |
| Free Cash Flow | $-8.46M | $-7.47M | $-13.14M | $-18.93M | $-19.53M | $-19.17M | $-17.24M | $-22.47M | $-24.50M | $-25.14M | $-26.91M | $-46.94M | $-38.09M | $-52.57M | $-29.84M | $-32.02M | $-30.73M | $-17.68M | $-11.81M | $-21.95M |
Passage Bio Dividends
Explore Passage Bio's dividend history, including dividend yield, payout ratio, and historical payments.
Passage Bio News
Read the latest news about Passage Bio, including recent articles, headlines, and updates.
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Extended cash runway into 1Q 2027 PHILADELPHIA, March 04, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided recent business highlights. “We are pleased to report strong performance in 2024 as we meaningfully advanced our PBFT02 program, delivering promising data in FTD-GRN patients showing robust, durable progranulin expression and early evidence of improvement in a disease progression biomarker.
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:
Passage Bio assumed with an Outperform at Wedbush
Wedbush assumed coverage of Passage Bio with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline of four programs and additional options to license IND-enabling research from UPenn supported Passage's upsized IPO, but the current valuation looks to be a "deep discount" compared to the potential that PBFT02 for frontotemporal dementia can achieve, the analyst tells investors.
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET.
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant)
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET.
Passage Bio Welcomes Tom Kassberg to Board of Directors
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases.
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 7:00 a.m. ET.
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal Dementias (ISFTD2024) in September 2024 Achieved alignment with Food and Drug Administration (FDA) on the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Completed out-licensing of pediatric lysosomal storage disease programs to GEMMA Biotherapeutics Strong balance sheet to support continued execution, with cash runway to fund operations extended to the end of Q2 2026 PHILADELPHIA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2024 and provided recent business highlights. “This has been a pivotal quarter for our company, marked by significant momentum in our upliFT-D trial, increased clarity around our strategy to expand PBFT02 into additional adult neurodegenerative indications, and out-licensing of our pediatric lysosomal storage disorder programs,” said Will Chou, M.D.
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 4:00 p.m. ET.
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of its Tachi Yamada Scholarship award.
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, May 14, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2024 and provided recent business highlights.
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, and Eden Fucci, senior vice president of technical operations, will participate in a virtual fireside chat at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024 at 9:00 a.m. ET.
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, March 04, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided recent business highlights.
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Stay on the Internet long enough – and it won't take too long, believe me – and you'll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns to outright conspiracy theories, the suits on Wall Street don't always get the love from retail investors.
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:00 a.m. ET.
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
PHILADELPHIA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of patients with frontotemporal dementia (FTD) with granulin (GRN) mutations. FTD is a form of early onset dementia with no approved disease-modifying therapies. Additionally, the company shared updated strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee.
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2023, and provided recent business highlights.
Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET.
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PASG.